Comparison of Tumor M2-Pyruvate Kinase (Tumor M2-PK), Carcinoembryonic Antigen (CEA), Carbohydrate Antigens CA 19-9 and CA 72-4 in the Diagnosis of Gastrointestinal Cancer

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5089-5093

  Schneider, Joachim ^a   Schulze, Guntram ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Institut für Labordiagnostik   (Germany)

Author keywords

CA 19 9; CA 72 4; CEA; Gastrointestinal cancer; Tumor M2 PK

Indexed keywords

CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR M2 PYRUVATE KINASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUTOANALYZER; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRUVATE KINASE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0842300413     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Scheefers-Borchel U, Scheefers H, Michel A, Will H, Fischer G, Basenau D, Dahlmann N, Laumen R, Mazurek S and Eigenbrodt E: Quantitative determination (ELISA) of pyruvate kinase type tumor M2. In: Klapdor R (ed.): Current Tumor Diagnosis, Applications, Clinical Relevance, Research-trends. W. Zuckerscherdt Verlag, München: 365-368, 1994.
2. Mazurek S, Boschek CB and Eigenbrodt E: The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenergetics Biomembranes 29: 315-330, 1997.
3. Ibsen KH, Orlando RA, Garrat KN, Hernandez AN, Giorlando S and Nungaray G: Expression of multimolecular forms of pyruvate kinase in normal, benign and malignant human breast tissue. Cancer Res 42: 888-892, 1982.
4. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, Scheefers H and Friis R: Double role for pyruvate kinase type M2 in expansion of phosphometabolite pools found in tumor cells. Critical Rev Oncogenesis 3: 91-115, 1992.
5. Hugo F, Fischer G and Eigenbrodt E: Quantitative detection of Tumor M2-PK in serum and plasma. Anticancer Res 19: 2753-2758, 1999.
6. Eigenbrodt E, Basenau D, Holthusen S, Mazurek S and Fischer G: Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res 17: 3153-3156, 1997.
7. Brinck U, Eigenbrodt E, Oehmke M, Mazurek S and Fischer G: L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases. Virch Arch 424: 177-185, 1994.
8. Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E and Usadel KH: The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 19: 2599-2602, 1999.
9. Balinsky B, Greengard O, Cayanis E and Head JF: Enzyme activities and isoenzyme patterns in human lung tumors. Cancer Res 44: 1058-1062, 1984.
10. Schneider J, Neu K, Grimm H, Velcovsky HG, Weisse G and Eigenbrodt E: Tumor M2-pyruvate-kinase in lung cancer patients-Immunohistochemical detection and disease monitoring. Anticancer Res 22: 311-318, 2002.
11. Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S and Seiffert UB: Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. Anticancer Res 17: 3031-3034, 1997.
12. Schneider J, Morr H, Velcovsky HG, Weisse G and Eigenbrodt E: Quantitative detection of Tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Cancer Detect Prevent 24: 531-535, 2000.
13. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K and Eigenbrodt E: Comparison of the tumor markers Tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 20: 5053-5058, 2000.
14. Schulze G: The tumor marker Tumor M2-PK: An application in diagnosis of gastrointestinal cancer. Anticancer Res 20: 4961-4965, 2000.
15. Cerwenka H, Aigner R, Bacher H, Werkgartner G, El-Shbrawi A, Quehenberger F and Mischinger HJ: TUM2-PK (Pyruvate kinase type tumor M2), CA 19-9 and CEA in patients with benign, malignant and metasasizing pancreatic lesions. Anticancer Res 19: 849-852, 1999.
16. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H and Klör HU: Tumor M2-Pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 20: 4965-4968, 2000.